诺华-话题@MedSci

#诺华#

235篇内容 | 5380人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1282673, encodeId=8ae612826e30e, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=紧追辉瑞！FDA授予诺华新型抗癌药LEE011治疗HR+/HER2-乳腺癌的突破性药物资格（BTD）, objectType=article, longId=74521, objectId=f237e452185, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f237e452185, replyNumber=0, likeNumber=69, createdTime=2016-08-07, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f237e452185, moduleTitle=紧追辉瑞！FDA授予诺华新型抗癌药LEE011治疗HR+/HER2-乳腺癌的突破性药物资格（BTD）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f237e452185)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282672, encodeId=f8d712826e21d, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=强生、诺华二季度报一起看：重磅药物贡献大！, objectType=article, longId=74004, objectId=6e71e4004b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e71e4004b6, replyNumber=0, likeNumber=82, createdTime=2016-07-30, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e71e4004b6, moduleTitle=强生、诺华二季度报一起看：重磅药物贡献大！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e71e4004b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282671, encodeId=f9f012826e100, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=抗癌药有望治疗帕金森？诺华将开展Tasigna 帕金森症临床试验, objectType=article, longId=73843, objectId=91fde384368, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91fde384368, replyNumber=0, likeNumber=67, createdTime=2016-07-28, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91fde384368, moduleTitle=抗癌药有望治疗帕金森？诺华将开展Tasigna 帕金森症临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91fde384368)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282669, encodeId=dee3128266931, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=安进危险！诺华 Enbrel仿制药获FDA专家委员会支持批准, objectType=article, longId=73506, objectId=5ee6e3506dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ee6e3506dc, replyNumber=0, likeNumber=93, createdTime=2016-07-24, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ee6e3506dc, moduleTitle=安进危险！诺华 Enbrel仿制药获FDA专家委员会支持批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ee6e3506dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282670, encodeId=875512826e00e, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华新发现可“直视”小分子药物工作机理, objectType=article, longId=73511, objectId=9f06e3511d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f06e3511d2, replyNumber=0, likeNumber=92, createdTime=2016-07-24, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f06e3511d2, moduleTitle=诺华新发现可“直视”小分子药物工作机理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f06e3511d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282668, encodeId=5d361282668d3, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华/Genetech单抗Xolair获FDA批准用于6至11岁哮喘患儿, objectType=article, longId=72752, objectId=9c5ae275275, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c5ae275275, replyNumber=0, likeNumber=66, createdTime=2016-07-15, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c5ae275275, moduleTitle=诺华/Genetech单抗Xolair获FDA批准用于6至11岁哮喘患儿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c5ae275275)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282667, encodeId=b286128266e1b, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华试验性肥大细胞增多症药物midostaurin整体缓解率达60%, objectType=article, longId=72200, objectId=be55e220004, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be55e220004, replyNumber=0, likeNumber=136, createdTime=2016-07-08, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be55e220004, moduleTitle=诺华试验性肥大细胞增多症药物midostaurin整体缓解率达60%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be55e220004)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282666, encodeId=466d128266633, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华与Xencor签署26亿美元协议，加强免疫肿瘤学（IO）资产, objectType=article, longId=71962, objectId=31b8e196232, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31b8e196232, replyNumber=0, likeNumber=66, createdTime=2016-07-02, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31b8e196232, moduleTitle=诺华与Xencor签署26亿美元协议，加强免疫肿瘤学（IO）资产, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31b8e196232)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282665, encodeId=6ada1282665e5, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华善宁（长效奥曲肽）惨遭KO：法国AAA公司神经内分泌肿瘤新药Lutathera年底将上市美国, objectType=article, longId=71757, objectId=3ed6e1757c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ed6e1757c0, replyNumber=0, likeNumber=88, createdTime=2016-06-30, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ed6e1757c0, moduleTitle=诺华善宁（长效奥曲肽）惨遭KO：法国AAA公司神经内分泌肿瘤新药Lutathera年底将上市美国, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ed6e1757c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282664, encodeId=a5cc1282664bf, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华善宁（长效奥曲肽）惨遭KO：法国AAA公司神经内分泌肿瘤新药Lutathera年底将上市美国, objectType=article, longId=71749, objectId=15ebe174998, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15ebe174998, replyNumber=0, likeNumber=77, createdTime=2016-06-30, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15ebe174998, moduleTitle=诺华善宁（长效奥曲肽）惨遭KO：法国AAA公司神经内分泌肿瘤新药Lutathera年底将上市美国, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15ebe174998)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282663, encodeId=7411128266397, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华抗癌药Jakavi达真性红细胞增多症III期临床主要终点, objectType=article, longId=71290, objectId=e56ee129027, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e56ee129027, replyNumber=0, likeNumber=0, createdTime=2016-06-22, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e56ee129027, moduleTitle=诺华抗癌药Jakavi达真性红细胞增多症III期临床主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e56ee129027)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282662, encodeId=5220128266276, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华联合卫材将在美国推出抗癌药Lenvima/Afinitor组合疗法, objectType=article, longId=70375, objectId=c875e0375c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c875e0375c6, replyNumber=0, likeNumber=0, createdTime=2016-06-11, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c875e0375c6, moduleTitle=诺华联合卫材将在美国推出抗癌药Lenvima/Afinitor组合疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c875e0375c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282661, encodeId=457d12826611a, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华Afinitor获欧盟批准治疗非功能性胃肠道和肺部神经内分泌肿瘤（NET）, objectType=article, longId=70023, objectId=a5f0e00232a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5f0e00232a, replyNumber=0, likeNumber=96, createdTime=2016-06-07, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5f0e00232a, moduleTitle=诺华Afinitor获欧盟批准治疗非功能性胃肠道和肺部神经内分泌肿瘤（NET）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5f0e00232a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282660, encodeId=f86c12826607a, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华突破性药物bimagrumab临床后期研究遭遇滑铁卢, objectType=article, longId=67207, objectId=b4376e2077b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4376e2077b, replyNumber=0, likeNumber=57, createdTime=2016-04-28, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4376e2077b, moduleTitle=诺华突破性药物bimagrumab临床后期研究遭遇滑铁卢, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4376e2077b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282659, encodeId=54e91282659af, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=喜报！诺华心衰药Entresto获NICE积极推荐, objectType=article, longId=65629, objectId=4a2f6562942, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a2f6562942, replyNumber=0, likeNumber=74, createdTime=2016-03-29, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a2f6562942, moduleTitle=喜报！诺华心衰药Entresto获NICE积极推荐, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a2f6562942)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282658, encodeId=c78d12826582d, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华Cosentyx单抗治疗银屑病患者52周时的疗效优于Stelara，表现为持久性皮损消退(PASI 90), objectType=article, longId=64414, objectId=a3da64414ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3da64414ca, replyNumber=0, likeNumber=58, createdTime=2016-03-09, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3da64414ca, moduleTitle=诺华Cosentyx单抗治疗银屑病患者52周时的疗效优于Stelara，表现为持久性皮损消退(PASI 90), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3da64414ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282657, encodeId=370b128265ecb, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=药不提当年勇：诺华心衰药物Entresto拟按真实世界有效性收费, objectType=article, longId=63306, objectId=1db4633067f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1db4633067f, replyNumber=0, likeNumber=59, createdTime=2016-02-18, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1db4633067f, moduleTitle=药不提当年勇：诺华心衰药物Entresto拟按真实世界有效性收费, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1db4633067f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282656, encodeId=7c1212826563d, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华抗癌药Odomzo获FDA加速批准用于局部晚期基底细胞癌, objectType=article, longId=54093, objectId=e95954093cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e95954093cd, replyNumber=0, likeNumber=57, createdTime=2015-07-30, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e95954093cd, moduleTitle=诺华抗癌药Odomzo获FDA加速批准用于局部晚期基底细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e95954093cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282655, encodeId=ecf81282655e3, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=心脏病重大里程碑！诺华心衰药Entresto（LCZ696）获FDA批准！, objectType=article, longId=53070, objectId=c4d1530e09f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4d1530e09f, replyNumber=0, likeNumber=44, createdTime=2015-07-10, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4d1530e09f, moduleTitle=心脏病重大里程碑！诺华心衰药Entresto（LCZ696）获FDA批准！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4d1530e09f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1282654, encodeId=a6d8128265464, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, objectTitle=诺华白血病药物Arzerra III期临床显著改善复发性CLL无进展生存期, objectType=article, longId=52073, objectId=0df1520e32c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0df1520e32c, replyNumber=0, likeNumber=72, createdTime=2015-06-17, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0df1520e32c, moduleTitle=诺华白血病药物Arzerra III期临床显著改善复发性CLL无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0df1520e32c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

诺华

2020-05-29发表于威斯康星

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

紧追辉瑞！FDA授予诺华新型抗癌药LEE011治疗HR+/HER2-乳腺癌的突破性药物资格（BTD）

2016-08-07

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

强生、诺华二季度报一起看：重磅药物贡献大！

2016-07-30

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

抗癌药有望治疗帕金森？诺华将开展Tasigna 帕金森症临床试验

2016-07-28

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

安进危险！诺华 Enbrel仿制药获FDA专家委员会支持批准

2016-07-24

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

诺华新发现可“直视”小分子药物工作机理

2016-07-24

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

诺华/Genetech单抗Xolair获FDA批准用于6至11岁哮喘患儿

2016-07-15

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

诺华试验性肥大细胞增多症药物midostaurin整体缓解率达60%

2016-07-08

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

诺华与Xencor签署26亿美元协议，加强免疫肿瘤学（IO）资产

2016-07-02

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

诺华善宁（长效奥曲肽）惨遭KO：法国AAA公司神经内分泌肿瘤新药Lutathera年底将上市美国

2016-06-30

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

诺华善宁（长效奥曲肽）惨遭KO：法国AAA公司神经内分泌肿瘤新药Lutathera年底将上市美国

2016-06-30

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

诺华抗癌药Jakavi达真性红细胞增多症III期临床主要终点

2016-06-22

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

诺华联合卫材将在美国推出抗癌药Lenvima/Afinitor组合疗法

2016-06-11

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

诺华Afinitor获欧盟批准治疗非功能性胃肠道和肺部神经内分泌肿瘤（NET）

2016-06-07

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

诺华突破性药物bimagrumab临床后期研究遭遇滑铁卢

2016-04-28

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

喜报！诺华心衰药Entresto获NICE积极推荐

2016-03-29

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

诺华Cosentyx单抗治疗银屑病患者52周时的疗效优于Stelara，表现为持久性皮损消退(PASI 90)

2016-03-09

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

药不提当年勇：诺华心衰药物Entresto拟按真实世界有效性收费

2016-02-18

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

诺华抗癌药Odomzo获FDA加速批准用于局部晚期基底细胞癌

2015-07-30

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

心脏病重大里程碑！诺华心衰药Entresto（LCZ696）获FDA批准！

2015-07-10

一叶知秋 (审核中...)

前往app查看评论内容

#诺华#

诺华白血病药物Arzerra III期临床显著改善复发性CLL无进展生存期

2015-06-17

科室
- - 订阅+
  - 更多科室
工具
服务